The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, with more than 400 patients in each trial. The company expects to report combined top-line results from the two studies in the second quarter of 2026, making the update a major test of the stock’s bull case.

Neumora is also trying to build a broader brain-disease pipeline beyond navacaprant. The company said NMRA-511 remains on track to report data in the second half of 2026 from a study in agitation linked to Alzheimer’s disease, with a Phase 2 trial expected to begin in the first quarter of 2027. Another drug candidate, NMRA-898, is being tested in healthy volunteers and patients with stable schizophrenia, with Phase 1 data also expected in the second half of 2026. Neumora ended the first quarter with $147.1 million in cash and cash equivalents, which it expects to fund operations into the third quarter of 2027.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company developing treatments for brain diseases, including depression, Alzheimer’s-related agitation, and schizophrenia.

While we acknowledge the potential of NMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.